Moderna, Inc. (NASDAQ:MRNA) Stake Lowered by Dorsey & Whitney Trust CO LLC

Dorsey & Whitney Trust CO LLC lowered its position in Moderna, Inc. (NASDAQ:MRNAFree Report) by 9.7% in the third quarter, Holdings Channel.com reports. The fund owned 5,132 shares of the company’s stock after selling 549 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Moderna were worth $530,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. State Street Corp increased its position in shares of Moderna by 1.1% during the second quarter. State Street Corp now owns 14,227,227 shares of the company’s stock valued at $1,728,608,000 after purchasing an additional 150,872 shares during the period. Geode Capital Management LLC increased its position in shares of Moderna by 0.9% during the second quarter. Geode Capital Management LLC now owns 6,302,497 shares of the company’s stock valued at $763,754,000 after purchasing an additional 57,540 shares during the period. Morgan Stanley increased its position in shares of Moderna by 19.1% during the fourth quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock valued at $752,133,000 after purchasing an additional 670,284 shares during the period. Capital World Investors increased its position in shares of Moderna by 0.5% during the second quarter. Capital World Investors now owns 3,940,872 shares of the company’s stock valued at $478,816,000 after purchasing an additional 21,282 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Moderna by 108.2% during the first quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock valued at $657,720,000 after purchasing an additional 1,984,458 shares during the period. Institutional investors and hedge funds own 64.51% of the company’s stock.

Insider Transactions at Moderna

In other news, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $103.90, for a total transaction of $1,558,500.00. Following the completion of the sale, the president now owns 1,516,063 shares in the company, valued at $157,518,945.70. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CFO James M. Mock sold 772 shares of the company’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $109.75, for a total value of $84,727.00. Following the completion of the sale, the chief financial officer now owns 3,632 shares in the company, valued at $398,612. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $103.90, for a total value of $1,558,500.00. Following the completion of the sale, the president now owns 1,516,063 shares of the company’s stock, valued at approximately $157,518,945.70. The disclosure for this sale can be found here. Insiders sold a total of 106,899 shares of company stock worth $10,732,838 over the last 90 days. 15.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

MRNA has been the topic of several recent analyst reports. Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target on the stock in a research note on Tuesday, January 2nd. JPMorgan Chase & Co. decreased their price target on Moderna from $93.00 to $90.00 and set a “neutral” rating on the stock in a research note on Friday, December 1st. Canaccord Genuity Group initiated coverage on Moderna in a research note on Wednesday, November 29th. They issued a “hold” rating and a $82.00 price target on the stock. The Goldman Sachs Group decreased their price target on Moderna from $269.00 to $231.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 price target on shares of Moderna in a research note on Friday, January 12th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $123.96.

View Our Latest Report on MRNA

Moderna Stock Performance

MRNA stock opened at $95.49 on Tuesday. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $177.37. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.35 and a current ratio of 2.46. The business has a fifty day moving average of $94.95 and a 200-day moving average of $96.81.

Moderna Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.